Home›Clinical trials›Georgia

GLP-1 clinical trials in Georgia: 23 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

23 GLP-1 clinical trials are recruiting at 48 sites in 23 cities across Georgia. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Georgia

  1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Brigham and Women's Hospital plans to enroll 6,000 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    2 sites in Georgia

    NCT05390892 on ClinicalTrials.gov. See whether you qualify.

  2. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

    Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

    2 sites in Georgia

    • Atlanta Research Center for Rheumatology, Marietta. 7703723962
    • Satilla Rheumatology & Internal Medicine, Waycross. 9125480710

    NCT06864026 on ClinicalTrials.gov. See whether you qualify.

  3. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    1 site in Georgia

    NCT06857942 on ClinicalTrials.gov. See whether you qualify.

  1. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Eli Lilly and Company plans to enroll 4,500 participants.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    4 sites in Georgia

    • Southeast Clinical Research Center, Dalton. 706-913-1779
    • Teak Research Consults, Lawrenceville
    • Gastrointestinal Specialists of Georgia, Marietta. 404-786-3100
    • Rophe Adult and Pediatric Medicine/SKYCRNG, Union City. 470-317-3604

    NCT07165028 on ClinicalTrials.gov. See whether you qualify.

  2. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Novo Nordisk A/S plans to enroll 460 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Children and teens 8 to 18, are overweight.

    4 sites in Georgia

    • Children's Healthcare Atlanta, Atlanta
    • Columbus Research Foundation, Columbus
    • Accel Research Sites-NeuroStudies, Decatur
    • Eastside Bariatric and Gen Surg, Snellville

    NCT07253285 on ClinicalTrials.gov. See whether you qualify.

  3. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Novo Nordisk A/S plans to enroll 2,500 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    4 sites in Georgia

    • Hope Clin Res & Wellness, Conyers
    • Center for Adv Res & Education, Gainesville
    • Endocrine Research Solutions, Inc, Roswell
    • North Georgia Clinical Research, Woodstock

    NCT07564414 on ClinicalTrials.gov. See whether you qualify.

  4. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Boehringer Ingelheim plans to enroll 600 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    4 sites in Georgia

    • Centricity Research, Endocrine Consultants, Columbus. 833-602-2368
    • Javara-Fayetteville-67354, Fayetteville. 833-602-2368
    • Balanced Life Health Care Solutions, Lawrenceville. 833-602-2368
    • Rophe Adult and Pediatric Medicine, Union City. 833-602-2368

    NCT07754461 on ClinicalTrials.gov. See whether you qualify.

  5. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Boehringer Ingelheim plans to enroll 1,590 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    3 sites in Georgia

    • Piedmont Hospital, Atlanta. 833-602-2368
    • Gastroenterology Associates of Central Georgia, Macon. 833-602-2368
    • EmVenio Research Center at Prime Healthcare - Riverdale, Riverdale. 833-602-2368

    NCT06632457 on ClinicalTrials.gov. See whether you qualify.

  6. A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

    Phase 3. Amgen plans to enroll 300 participants.

    A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

    3 sites in Georgia

    • Nsc Research, Johns Creek
    • Rophe Adult and Pediatric Medicine/Sky Clinical Research Network Group, Union City
    • North Georgia Clinical Research, Woodstock

    NCT07575399 on ClinicalTrials.gov. See whether you qualify.

  7. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Boehringer Ingelheim plans to enroll 1,800 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    2 sites in Georgia

    • Gastroenterology Associates of Central Georgia, Macon. 833-602-2368
    • EmVenio Research Center at Prime Healthcare - Riverdale, Riverdale. 833-602-2368

    NCT06632444 on ClinicalTrials.gov. See whether you qualify.

The other 13 studies recruiting in Georgia

  1. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Eli Lilly and Company plans to enroll 800 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    2 sites in Georgia

    NCT07153471 on ClinicalTrials.gov. See whether you qualify.

  2. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Eli Lilly and Company plans to enroll 125 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in Georgia

    • Children's Healthcare of Atlanta - Center for Advanced Pediatrics, Atlanta. 404-712-4731

    NCT06672549 on ClinicalTrials.gov. See whether you qualify.

  3. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

    Phase 3. Eli Lilly and Company plans to enroll 150 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 12 to 17, have obesity.

    1 site in Georgia

    • Children's Healthcare of Atlanta - Center for Advanced Pediatrics, Atlanta

    NCT06672939 on ClinicalTrials.gov. See whether you qualify.

  4. A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

    Phase 3. Eli Lilly and Company plans to enroll 1,000 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

    Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

    1 site in Georgia

    • Teak Research Consults, Lawrenceville

    NCT07202884 on ClinicalTrials.gov. See whether you qualify.

  5. Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. VA Office of Research and Development plans to enroll 622 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    1 site in Georgia

    • Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur. 404-321-6111

    NCT07218354 on ClinicalTrials.gov. See whether you qualify.

  6. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Kailera plans to enroll 1,200 participants.

    A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    1 site in Georgia

    • Kailera Clinical Site, Albany

    NCT07284979 on ClinicalTrials.gov. See whether you qualify.

  7. Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes

    Phase 3. Emory University plans to enroll 20 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 65+, women only, have type 2 diabetes, BMI 27+.

    1 site in Georgia

    NCT07428746 on ClinicalTrials.gov. See whether you qualify.

  8. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. AstraZeneca plans to enroll 1,200 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Georgia

    • Research Site, Lilburn

    NCT07662213 on ClinicalTrials.gov. See whether you qualify.

  9. A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

    Phase 3. Novo Nordisk A/S plans to enroll 285 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Adults 18+, are overweight, BMI 27+.

    1 site in Georgia

    • Hope Clin Res & Wellness, Conyers

    NCT07745504 on ClinicalTrials.gov. See whether you qualify.

  10. A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Eli Lilly and Company plans to enroll 240 participants.

    A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    4 sites in Georgia

    • Balanced Life Health Care Solutions/SKYCRNG, Lawrenceville. 770-696-4541
    • Physicians Research Associates, Lawrenceville. 678-252-2375
    • Rophe Adult and Pediatric Medicine/SKYCRNG, Union City. 470-317-3604
    • North Georgia Clinical Research, Woodstock. 678-494-5735

    NCT06897475 on ClinicalTrials.gov. See whether you qualify.

  11. A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type

    Phase 2. Antag Therapeutics plans to enroll 150 participants.

    A study testing whether an investigational medicine from Antag Therapeutics, AT673, can help people who are overweight lower blood sugar and lose weight.

    Who can join. Adults 18+, have type 2 diabetes, BMI 27+.

    3 sites in Georgia

    NCT07724340 on ClinicalTrials.gov. See whether you qualify.

  12. Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide

    Phase 2. Yale University plans to enroll 30 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18+, have alcohol use disorder, BMI 23+.

    1 site in Georgia

    NCT07040592 on ClinicalTrials.gov. See whether you qualify.

  13. Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants

    Phase 2. Biomea Fusion Inc plans to enroll 60 participants.

    A study testing whether an investigational medicine from Biomea Fusion, icovamenib, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 70, have type 2 diabetes, BMI 25+.

    1 site in Georgia

    • David Kavtaradze MD, Inc, Cordele

    NCT07502508 on ClinicalTrials.gov. See whether you qualify.

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
Written and edited by John SamarasAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.